The effects of mandatory prescribing of thiazides for newly treated, uncomplicated hypertension: Interrupted time-series analysis

PLoS Medicine

Volumn 4, Issue 7, 2007, Pages 1178-1186

  Fretheim, Atle ^a   Håvelsrud, Kari ^a   MacLennan, Graeme ^b   Kristoffersen, Doris Tove ^a   Oxman, Andrew D ^a  

^a NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ARTICLE; BLOOD PRESSURE; DRUG COST; GENERAL PRACTICE; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NORWAY; PRESCRIPTION; REIMBURSEMENT; STATISTICAL SIGNIFICANCE; TIME SERIES ANALYSIS; CLINICAL PRACTICE; DRUG UTILIZATION; ECONOMICS; STATISTICS; TIME;

ANTIHYPERTENSIVE AGENTS; DRUG UTILIZATION; HUMANS; HYPERTENSION; INSURANCE, HEALTH, REIMBURSEMENT; NORWAY; PHYSICIAN'S PRACTICE PATTERNS; THIAZIDES; TIME FACTORS;

EID: 34547591124     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0040232     Document Type: Article

References (17)

1. Rønning Meditor (2006) Drug consumption in Norway 2001-2005. Oslo: The Norwegian Institute of Public Health. 130 p.
2. Fretheim A, Aaserud M, Oxman AD (2003) The potential savings of using thiazides as the first choice antihypertensive drug: Cost-minimisation analysis. BMC Health Serv Res 3: 18.
3. Vihovde MB (1999) Spørsmål til Helseministeren, Stortingets spørretime 24. November 1999. Available: http://www.stortinget.no/spti/ dw-o1999112405-021. html. Accessed 31 May 2007.
4. Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE (2003) Interrupted time series designs in health technology assessment: Lessons from two systematic reviews of behavior change strategies. Int J Technol Assess Health Care 19: 613-623.
5. Fretheim A, Oxman AD, Havelsrud K, Treweek S, Kristoffersen DT, et al. (2006) Rational prescribing in primary care (RaPP): A cluster randomized trial of a tailored intervention. PLoS Med 3: e134. doi:10.1371/journal.pmed.0030134.
6. Madsen S, Bryn E, Christensen HM (2004) Lavdose tiazid skal prøves først ved ukomplisert hypertensjon. Nytt om legemidler 27: 7-8.
7. Mayor S (2005) Doctors urged to present views in an objective way to the media. BMJ 335: 1289.
8. Hafstad A (2003) Taper 200 mill. på dyre piller. Aftenposten (September 9) 1.
9. Statistics Norway (2005) How much is it worth...? Available: http://www.ssb. no/kpi_en/kpicalc.html. Accessed 31 May 2007.
10. Walsh J, McDonald K, Shojania K, Sundaram V, Nayal S, et al. (2005) Hypertension care. Rockville, Maryland: Agency for Healthcare Research and Quality. 98 p.
11. Fretheim A, Aaserud M, Oxman AD (2006) Rational prescribing in primary care (RaPP): Economic evaluation of an intervention to improve professional practice. PLoS Med 3: e216. doi:10.1371/journal.pmed.0030216.
12. Vollebæk LE (2004) Ullevål samlet mot blodtrykksvedtak. Dagens Medisin (February 26):
13. Wazana A (2000) Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA 283: 373-380.
14. MacKinnon NJ, Kumar R (2001) Prior authorization programs: A critical review of the literature. J Manag Care Pharm 7: 297-302.
15. Lexchin J (2002) Effects of restrictive formularies in the ambulatory care setting. Am J Manag Care 8: 69-76.
16. Aaserud M, Dahlgren AT, Sturm H, Kosters JP, Hill S, et al. (2006) Pharmaceutical policies: Effects on rational drug use, an overview of 13 reviews (protocol). Cochrane Database Syst Rev 2006: CD004397.
17. Aaserud M, Dahlgren AT, Kosters JP, Oxman AD, Ramsay C (2006) Pharmaceutical policies: Effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev 2006: CD005979.